Literature DB >> 20191378

Sensitive spectrofluorimetric method of analysis for venlafaxine in spiked rat plasma and formulations.

Sheikh Shahnawaz1, Zaki Siddiqui, Quaisul Hoda.   

Abstract

A simple, sensitive, accurate and affordable spectrofluorimetric method was developed and validated for the determination of venlafaxine, both in marketed preparations as well as in spiked rat plasma. Venlafaxine depicted strong native fluorescence property in freshly prepared 0.05 M sulphuric acid. The excitation and emission wavelengths were found to be 237.0 nm and 301.0 respectively. Effect of variations in pH, temperature, concentration, change in molarities of different solvents, and effect of excipients were studied. The calibration graph in case of dosage forms and in spiked plasma was found to be rectilinear in the concentrations of 15-600 ng/ml and 20-650 ng/ml respectively. The intra- day and inter-day accuracy measurements of VEN in formulations ranged from 0.29 to 0.44% and 0.27 to 0.49%, respectively. The intra-day and inter-day accuracy in measurement of VEN in plasma ranged from 0.062 to 2.26% and 0.52 to 2.32%, respectively. The limit of detection (LOD) was found to be 6.0 ng/mL and 4.0 ng/mL in plasma and formulations respectively. The mean recovery of VEN from plasma was 97.46.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20191378     DOI: 10.1007/s10895-010-0624-2

Source DB:  PubMed          Journal:  J Fluoresc        ISSN: 1053-0509            Impact factor:   2.217


  11 in total

1.  Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia.

Authors:  M Tzanakaki; M Guazzelli; I Nimatoudis; N P Zissis; E Smeraldi; F Rizzo
Journal:  Int Clin Psychopharmacol       Date:  2000-01       Impact factor: 1.659

2.  Liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for simultaneous determination of venlafaxine and its active metabolite O-desmethyl venlafaxine in human plasma.

Authors:  Jignesh Bhatt; Arvind Jangid; Gantala Venkatesh; Gunta Subbaiah; Sadhana Singh
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-10-24       Impact factor: 3.205

3.  Use of vancomycin silica stationary phase in packed capillary electrochromatography. II. Enantiomer separation of venlafaxine and O-desmethylvenlafaxine in human plasma.

Authors:  S Fanali; S Rudaz; J L Veuthey; C Desiderio
Journal:  J Chromatogr A       Date:  2001-06-01       Impact factor: 4.759

4.  Rapid determination of venlafaxine and O-desmethylvenlafaxine in human plasma by high-performance liquid chromatography with fluorimetric detection.

Authors:  R L Vu; D Helmeste; L Albers; C Reist
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-12-05

Review 5.  Schizophrenia: genesis, receptorology and current therapeutics.

Authors:  B Capuano; I T Crosby; E J Lloyd
Journal:  Curr Med Chem       Date:  2002-03       Impact factor: 4.530

6.  Quantification of venlafaxine and O-desmethylvenlafaxine in human serum using HPLC analysis.

Authors:  R Waschgler; W Moll; P König; A Conca
Journal:  Int J Clin Pharmacol Ther       Date:  2004-12       Impact factor: 1.366

7.  A high-performance liquid chromatographic method for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in biological fluids.

Authors:  D R Hicks; D Wolaniuk; A Russell; N Cavanaugh; M Kraml
Journal:  Ther Drug Monit       Date:  1994-02       Impact factor: 3.681

8.  A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs.

Authors:  Charlotte Duverneuil; Geoffroy Lorin de la Grandmaison; Philippe de Mazancourt; Jean-Claude Alvarez
Journal:  Ther Drug Monit       Date:  2003-10       Impact factor: 3.681

9.  Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.

Authors:  Andre De Nayer; Stefaan Geerts; Leo Ruelens; Michel Schittecatte; Eugeen De Bleeker; Ignace Van Eeckhoutte; Jean-Luc Evrard; Paul Linkowski; Pierre Fossion; Sophie Leyman; Annick Mignon
Journal:  Int J Neuropsychopharmacol       Date:  2002-06       Impact factor: 5.176

10.  Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.

Authors:  Eric Michael Kaplan
Journal:  Clin Ther       Date:  2002-07       Impact factor: 3.393

View more
  1 in total

1.  Multiple-reaction monitoring (MRM) LC-MS/MS quantitation of venlafaxine and its O-desmethyl metabolite for a preclinical pharmacokinetic study in rabbits.

Authors:  Abdul Aala Fazli; Bala Krishna Panigrahy; Varinder Kumar; Syed Naiem Raza; Bilal Ahmad Zarger; Taha Umair Wani; Shavej Ahmad; Arshad Khuroo; Nisar Ahmad Khan
Journal:  Sci Rep       Date:  2022-06-04       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.